CD47, CD200 and PD-L1 have high profiles in immunotherapy research, as targets that can help tumours evade both the innate and adaptive immune systems. Targeting these responses in combination has exciting potential, so we developed these new research tools to help investigators explore it.
Mouse-anti-mouse bispecific antibody with silenced Fc effector function
Matched to host species for low immunogenicity
High purity and low endotoxin content for in vivo applications
Defined stoichiometry of binding regions
Not your ideal pair of targets? ‘Mix-and-match’ from our other immunotherapy targets to build your own custom bispecific. You can check out our range of antibodies against mouse immune checkpoint targets here.